A Quality Initiative of the Program in Evidence-based Care (PEBC), Cancer Care Ontario (CCO) Pemetrexed Monotherapy for the Maintenance Treatment of Patients with Locally Advanced or Metastatic Non-Small Cell Lung Cancer with Non-Squamous Histology

Shi‐Bo Cheng(Shandong University), Angus Robinson(Royal Sussex County Hospital)
Unknown
January 1, 2014
Cited by 0

Related Papers

Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, platform randomised controlled trial
|The Lancet|2015|2k
Abiraterone for Prostate Cancer Not Previously Treated with Hormone Therapy
|New England Journal of Medicine|2017|1.8k
Olaparib in patients with metastatic castration-resistant prostate cancer with DNA repair gene aberrations (TOPARP-B): a multicentre, open-label, randomised, phase 2 trial
|The Lancet Oncology|2019|649
Gemcitabine and capecitabine with or without telomerase peptide vaccine GV1001 in patients with locally advanced or metastatic pancreatic cancer (TeloVac): an open-label, randomised, phase 3 trial
|The Lancet Oncology|2014|374
Abiraterone acetate and prednisolone with or without enzalutamide for high-risk non-metastatic prostate cancer: a meta-analysis of primary results from two randomised controlled phase 3 trials of the STAMPEDE platform protocol.
|BORIS (University Library Bern)|2022|311